SequelSEC

Propanc Biopharma, Inc. PPCB

Pharmaceutical Preparations · CIK 0001517681 · Fiscal year ends 0630

Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$18.19M
Fiscal year ended 2026-06-30
Free cash flow
-$5.69M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$47.90KMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.55x21th

Propanc Biopharma, Inc. (PPCB) reported net income of -$18.86M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Propanc Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Propanc Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$28.06K$30.52K$28.99K
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$18.19M-$57.28M-$1.54M-$1.78M-$1.99M-$1.81M-$3.49M-$2.61M-$3.96M-$5.74M
Net income-$18.86M-$58.92M-$1.82M-$2.66M-$2.66M-$2.03M-$4.74M-$5.76M-$7.04M-$7.87M
Research & development$625.48K$223.72K$248.10K$247.92K$256.05K$230.96K$179.99K$260.34K$1.83M$971.77K
Weighted-average diluted sharesshares 1.12MUnavailableUnavailableshares 1.74MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$18.86M-$58.92M-$1.95M-$2.79M-$2.71M-$2.14M-$4.88M-$5.76M-$7.04MUnavailable
Income tax expenseUnavailableUnavailable-$129.13K-$129.84K-$54.98K-$113.42K-$134.73K-$115.44K-$179.31K-$305.67K
Diluted EPS$-17.62$-371.22$-1,420.53$-1.80$-49.23UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$670.61K$108.95K$1.25M$1.50M$1.71M$1.55M$3.28M$2.33M$2.10M$4.74M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Propanc Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailable$4.07K$2.26K$67.01KUnavailableUnavailableUnavailable
Total assets$12.78M$19.63M$72.36K$60.33K$81.65K$13.10K$98.52K$101.65K$71.39K$95.07K
Current assets$8.54M$8.35M$25.44K$19.04K$15.03K$6.60K$69.02K$91.13K$60.89K$81.98K
Total liabilities$3.38M$5.73M$3.85M$3.18M$3.11M$3.08M$3.74M$4.40MUnavailableUnavailable
Current liabilities$3.35M$5.58M$3.79M$3.16M$3.06M$3.08M$3.74M$4.40M$6.82M$5.54M
Total equity incl. NCI$9.40M$13.91M-$3.78M-$3.12M-$3.02M-$3.07M-$3.64M-$4.30M-$6.75M-$5.44M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$537.92K$399.32K$390.54K$926.44K$624.58K$1.56M$1.66M$4.70M$3.48M
Accounts payable$1.13M$1.25M$1.21M$966.72K$943.02K$1.00M$842.16K$917.34K$1.16M$483.51K

Cash flow

Propanc Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow-$5.68M-$405.17K-$935.12K-$1.11M-$1.44M-$1.15M-$1.85M-$2.06M-$2.18M-$2.05M
Capital expenditures$4.93KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.87KUnavailableUnavailable
Investing cash flow-$4.93KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$2.87KUnavailableUnavailable
Financing cash flow$6.46M$490.76K$941.89K$1.11M$1.49M$1.06M$1.89M$2.12M$2.40M$2.10M
Net change in cash$819.92K-$9.00K$11.04K$5.98K$1.81K-$64.75K$64.61K-$17.53K-$49.12KUnavailable
Stock-based compensation$8.50M$4.62MUnavailable$2.41K$72.51K$82.87K$300.42KUnavailable$516.15K$1.69M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Propanc Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flow-$5.69MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$2.06MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.55x1.50x0.01x0.01x0.00x0.00x0.02x0.02x0.01x0.01x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailable0.04xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PPCB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-25View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.